1. Scrip
  2. >>Drug Pricing

Pharma Firms Welcome 'Pragmatic' EU Reforms But Concerns Persist

 
• By Kevin Grogan

The European parliament has voted for legislation it says will lead to fairer, more accessible healthcare. The continent's drugmakers are still not wholly convinced.

EFPIA leadership
David Loew, Nathalie Moll, Lars Fruergaard Jørgensen (Novo Nordisk CEO and EFPIA president) and Stefan Oelrich (head of pharma at Bayer and EFPIA first vice president) • Source: EFPIA

Europe's drugmakers have been reflecting on a pivotal week for the sector which saw the European parliament vote in favor of an amended version of the high-profile package of new legislation to regulate the pharmaceutical industry.

MEPs overwhelmingly backed the legislative package, which includes a wide range of proposals for the pharma industry

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Hengrui Set For Biggest Biopharma IPO So Far This Year

 
• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.